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Gene polymorphismsLeptin is abnormally elevated in the plasma of patients with systemic lupus erythematosus (SLE), where it is
thought to promote and/or sustain pro-inﬂammatory responses. Whether this association could reﬂect an
increased genetic susceptibility to develop SLE is not known, and studies of genetic associations with
leptin-related polymorphisms in SLE patients have been so far inconclusive. Here we genotyped DNA sam-
ples from 15,706 SLE patients and healthy matched controls from four different ancestral groups, to corre-
late polymorphisms of genes of the leptin pathway to risk for SLE. It was found that although several SNPs
showed weak associations, those associations did not remain signiﬁcant after correction for multiple test-
ing. These data do not support associations between deﬁned leptin-related polymorphisms and increased
susceptibility to develop SLE.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
The etiopathogenesis of systemic lupus erythematosus (SLE) gener-
ally considers an involvement of environmental factors (including epi-
genetic changes) that could trigger abnormal autoimmune responses,
facilitated by sex and hormones, in individuals that carry a predisposing
genetic background [1]. Therefore, in SLE multiple genetic variants
could create favorable conditions for a heightened sensitivity of
autoreactive cells to an increased stimulation/activation.
Our groupandothers havepreviously shown that leptin is abnormally
elevated in SLE patients [2,3]. We also showed that leptin in mice could
promote SLE autoimmunity [4,5].Whether theseﬁndings underlie genet-
ic association(s) between selected leptin polymorphisms and SLE is not
known. A recent study suggested an association of a leptin receptor
gene polymorphism (LEPRQ223R) with increased susceptibility of SLE
in 100 Kashmiri individuals [6]. Since analyses on larger numbers of SLE
patients and in multiple ethnic groups would better delineate the possi-
bility of association(s) between leptin-related genes and increased risk
for SLE, we performed genetic association studies for single nucleotide
polymorphisms (SNPs) within multiple leptin-related genes. Criteria for
selection were based on the following considerations. Leptin gene (LEP)
polymorphisms [7] were studied because of their possible roles in abnor-
mal function/catabolismof leptin. For leptin receptor (LEPR), which exists
in six alternatively spliced forms with cytoplasmic domains of different
length [8], we assessed polymorphisms of all isoforms [9] because any
of them might inﬂuence catabolism and/or sustain leptin activity. The
polymorphism of PPARG [10–12] was also studied because leptin can
downregulate PPAR-γ expression for a subsequent increase in the release
of pro-inﬂammatory IL-1β, IL-6 and TNF-α [13,14]. Finally, the polymor-
phism of the growth hormone secretagogue receptor GHSRwas studied
because its opposing action on leptin results in the inhibition of the
same pro-inﬂammatory cytokines [15,16].
Haplotype-tagging SNPs selected from these genes were genotyped
by a customized SNP genotyping-array and assessed for association
with SLE in 15,706 case-control subjects from four different ancestral
groups including European American (EA), African American (AA), East
Asian (AS) and Hispanic enriched for the Amerindian-European admix-
ture (HS).
2. Materials and methods
2.1. Subjects' samples collection and SNP genotyping
To test association of LEPR, PPARG, GHSR and LEPwith SLE, we used a
large collection of samples from case-control subjects frommultiple eth-
nic groups. These samples were from the collaborative Large Lupus Asso-
ciation Study 2 (LLAS2) and were contributed by participating
institutions in the United States, Asia and Europe. All SLE patients met
the American College of Rheumatology (ACR) criteria for the classiﬁca-
tion of SLE [17]. LLAS2 samples were processed at the Lupus Genetics
Studies Unit of the Oklahoma Medical Research Foundation (OMRF).
SNP genotypingwas carried out on the Illumina iSelect platform. Subjectswith individual genotyping call rate b0.90 were removed because of low
data quality. Subjects that were duplicated or ﬁrst degree related were
also removed. Both principal component analysis and global ancestry es-
timation based on347 ancestry informativemarkers (AIMs)were used to
detect population stratiﬁcation and admixture, as described in another
LLAS2 report [18]. After removing genetic outliers, a ﬁnal dataset of
15,706 unrelated subjects (8269 cases vs. 7437 controls) was obtained.
According to genetic ancestry, subjects were grouped into four an-
cestral groups including European American (3966 cases vs. 3543 con-
trols), African American (1527 cases vs. 1812 controls), East Asian
(1272 cases vs. 1270 controls) and Hispanic enriched for the
Amerindian-European admixture (1504 cases vs. 812 controls).
The study was approved by the Human Subject Institutional Review
Boards or the Ethic Committee of each institution. All subjects were en-
rolled after informed consent had been obtained.
2.2. SNP selection and statistical analysis
To avoid the genotyping of all SNPs for the genes of interest yet cap-
ture themajority of diversity within each region, we selected haplotype
tag SNPs for genotyping according to the Hapmap Project (http://
hapmap.ncbi.nlm.nih.gov/cgi-perl/gbrowse/hapmap24_B36/; HapMap
public release #24 of 11/26/2008). In addition, SNPs with potential
functional consequences were selected as well for testing. In total, we
selected 9 SNPs for LEP, 17 SNPs for LEPR, 5 SNPs for GHSR and 16
SNPs for PPARG, at an average density of 8.2 kb per SNP. 32 SNPs that
passed data cleaning and quality control measures (7 SNPs for LEP, 10
SNPs for LEPR, 3 SNPs forGHSR and 12 SNPs for PPARG, Table 1)were ge-
notyped on the Illumina iSelect platform and subsequently used for ge-
netic association test.
The Hardy–Weinberg equilibrium (HWE) test threshold was set at
P N 0.01 for controls and P N 0.0001 for cases. SNPs failing the HWE test
were excluded from association test. SNPs showing genotyping missing
rate N5% or showing signiﬁcantly different genotyping missing rate be-
tween cases and controls (missing rate N2% and Pmissing b 0.05) were ex-
cluded from association test. In each ancestral group, SNPswere assessed
for association with SLE under a logistic regression model adjusting for
gender and the ﬁrst 3 principal components estimated using AIMs. The
trans-ancestry meta-analysis was conducted across all four ancestral
groups. For each SNP, if the Cochran's Q statistic showed no evidence of
genetic heterogeneity (P N 0.05), a ﬁxed effect model was applied. Other-
wise, a random effectmodel was used. All analyses described abovewere
performed using PLINK v1.07 [19]. Pairwised LD values shown in Fig. 1
were calculated using Haploview 4.2 [20]
3. Results
3.1. Genetic association between leptin-related polymorphisms and human
SLE
To test the possibility of common leptin-related variants predispos-
ing to SLE, genetic association studies using htSNPs for the four selected
Table 1
Association of SNPs in Leptin-related genes with SLE susceptibility.
Tested EA AA AS HS Meta-analysis
Frequency Frequency Frequency Frequency
SNP Gene Location Allele SLE CTRL P OR SLE CTRL P OR SLE CTRL P OR SLE CTRL P OR P OR
rs3806318 LEPR chr1:65657945 G 27.2% 26.8% 0.35 1.04 5.3% 5.4% 0.91 1.01 13.8% 14.0% 0.89 0.99 17.6% 18.4% 0.95 1.01 0.46 1.02
rs9436740 LEPR chr1:65664489 A 27.7% 28.0% 0.84 0.99 47.9% 48.4% 0.93 1.00 18.3% 20.2% 0.077 0.88 26.9% 26.2% 0.29 1.08 0.65 0.99
rs12029311 LEPR chr1:65755938 A 0.3% 0.2% 0.33 1.45 0.2% 0.3% 0.14 0.45 20.4% 21.3% 0.41 0.94 7.7% 6.5% 0.65 1.06 0.62 0.97
rs1409802 LEPR chr1:65793939 A 24.4% 24.4% 0.92 1.00 18.5% 18.3% 0.54 1.04 78.9% 79.3% 0.70 0.97 24.1% 25.4% 0.22 0.92 0.65 0.99
rs4370791 LEPR chr1:65824816 G 25.7% 25.4% 0.69* 1.02 29.6% 28.6% 0.31 1.06 80.7% 80.2% 0.63 1.04 26.8% 27.2% 0.68* 0.97 0.42 1.02
rs1137101 LEPR chr1:65831101 G 42.8% 43.0% 0.69 0.99 56.0% 54.7% 0.13 1.08 86.8% 86.8% 0.98 1.00 41.9% 45.3% 0.012* 0.85 0.59 0.99
rs3790422 LEPR chr1:65838587 A 36.7% 37.0% 0.74 0.99 56.5% 55.5% 0.22 1.07 87.8% 87.0% 0.42 1.07 41.0% 43.3% 0.037 0.88 0.81 0.99
rs8179183 LEPR chr1:65848540 C 18.8% 18.0% 0.11 1.07 20.3% 18.5% 0.23 1.08 7.4% 7.7% 0.63 0.95 18.0% 17.2% 0.54 1.05 0.067 1.06
rs6690625 LEPR chr1:65850178 C 17.7% 17.8% 0.82 0.99 33.2% 31.5% 0.097* 1.10 78.6% 78.6% 0.98 1.00 25.9% 28.7% 0.0011 0.79 0.54 0.98
rs1892535 LEPR chr1:65869769 A 17.0% 17.3% 0.70 0.98 14.9% 14.6% 0.61 1.04 76.5% 76.0% 0.72 1.02 25.0% 26.8% 0.0068 0.82 0.31 0.97
rs6785890 PPARG chr3:12310816 A 24.0% 24.7% 0.26 0.96 28.0% 28.3% 0.88 1.01 49.8% 52.4% 0.090 0.91 37.3% 37.0% 0.076* 0.89 0.031 0.94
rs17036188 PPARG chr3:12315925 G 2.6% 3.0% 0.11 0.84 3.4% 3.4% 0.47 1.11 27.6% 29.7% 0.14 0.91 1.7% 2.2% 0.41 0.83 0.0655 0.91
rs10510410 PPARG chr3:12321738 C 23.6% 24.4% 0.26 0.96 29.7% 30.6% 0.52 0.96 29.1% 31.5% 0.07 0.90 35.6% 34.8% 0.28 0.93 0.024 0.94
rs12633551 PPARG chr3:12335494 A 2.8% 3.3% 0.022 0.80 0.7% 0.4% 0.071 1.93 24.4% 26.1% 0.19 0.92 1.4% 2.0% 0.28 0.77 0.025 0.89
rs4145574 PPARG chr3:12347074 G 22.2% 23.1% 0.13 0.94 21.1% 21.1% 0.99 1.00 28.1% 30.5% 0.077 0.89 32.6% 33.6% 0.031* 0.86 0.0080 0.93
rs2959273 PPARG chr3:12417731 A 39.4% 38.9% 0.61 1.02 20.6% 21.4% 0.57 0.96 43.9% 44.0% 0.97 1.00 27.6% 29.1% 0.97 1.00 0.90 1.00
rs4135275 PPARG chr3:12418844 G 19.9% 19.2% 0.18 1.06 5.6% 5.7% 0.73 0.96 46.9% 47.6% 0.59 0.97 24.5% 22.2% 0.21 1.10 0.30 1.03
rs709151 PPARG chr3:12429999 A 35.1% 34.6% 0.72 1.01 13.3% 13.5% 0.68 1.03 42.7% 43.3% 0.71 0.98 22.7% 24.4% 0.69 0.97 0.93 1.00
rs1175543 PPARG chr3:12441433 G 35.2% 35.1% 0.93 1.00 13.4% 13.7% 0.71 1.03 43.2% 43.3% 1.00 1.00 23.0% 24.5% 0.77 0.98 0.97 1.00
rs1175544 PPARG chr3:12442044 A 33.1% 32.4% 0.32 1.04 10.3% 10.7% 0.86 0.98 40.2% 40.9% 0.60 0.97 21.5% 22.8% 0.89 0.99 0.71 1.01
rs1797912 PPARG chr3:12445239 C 37.1% 36.9% 0.97 1.00 14.3% 13.9% 0.29* 1.08 43.6% 45.0% 0.35 0.95 24.8% 26.3% 0.91 0.99 0.92 1.00
rs3856806 PPARG chr3:12450557 A 11.1% 12.3% 0.023 0.88 5.5% 5.8% 0.89 1.02 18.4% 18.8% 0.78 0.98 9.9% 10.9% 0.11 0.84 0.024 0.92
rs509035 GHSR chr3:173646143 A 29.0% 29.5% 0.27 0.96 8.9% 8.7% 0.83 1.02 45.5% 47.3% 0.25 0.94 33.3% 30.2% 0.20 1.09 0.45 0.98
rs2948694 GHSR chr3:173647857 G 10.4% 10.3% 0.83 1.01 10.1% 10.6% 0.65 0.96 35.0% 33.8% 0.44 1.05 13.7% 15.3% 0.019 0.81 0.61 0.98
rs572169 GHSR chr3:173648421 A 28.8% 29.6% 0.17 0.95 8.9% 8.9% 0.89 0.99 45.8% 47.8% 0.19 0.93 33.0% 30.2% 0.28 1.08 0.22 0.97
rs2278815 LEP chr7:127669087 G 44.7% 44.6% 0.97 1.00 85.3% 86.4% 0.17 0.90 24.8% 23.1% 0.16 1.10 51.7% 49.7% 0.59 1.04 0.74 1.01
rs12706832 LEP chr7:127674375 A 45.3% 45.1% 0.77 1.01 78.3% 80.6% 0.0063 0.84 25.6% 23.7% 0.15 1.10 50.9% 49.7% 0.98 1.00 0.78 0.99
rs10244329 LEP chr7:127675925 T 49.9% 49.8% 0.92 1.00 47.5% 46.1% 0.26 1.06 74.5% 76.3% 0.16 0.91 47.5% 48.1% 0.91 1.01 0.92 1.00
rs11760956 LEP chr7:127678323 A 36.6% 37.0% 0.70 0.99 18.6% 16.7% 0.14 1.10 21.2% 20.9% 0.78 1.02 42.2% 38.8% 0.16 1.09 0.33 1.03
rs10954173 LEP chr7:127678676 A 36.6% 37.1% 0.72 0.99 18.4% 16.7% 0.16 1.10 21.2% 20.8% 0.74 1.02 42.3% 38.8% 0.16 1.10 0.32 1.03
rs3828942 LEP chr7:127681541 A 43.2% 43.5% 0.64 0.98 19.5% 17.7% 0.029 1.16 74.4% 76.4% 0.10 0.90 42.2% 41.6% 0.41 1.05 0.86 1.00
rs11761556 LEP chr7:127684305 C 45.3% 45.4% 0.91 1.00 82.2% 83.0% 0.38 0.94 26.5% 24.6% 0.12 1.11 51.7% 50.5% 0.98 1.00 0.70 1.01
Position of each SNP is based on NCBI36/hg18. Signiﬁcant association signals (P b 0.05) are highlighted in italics and bold. For SNPs not passing our criteria of quality control, the P value is annotated with “*”.
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Fig. 1. SNPs in leptin-related genes assessed for associationwith SLE. Genomic structure, SNP location and pairwise linkage disequilibrium (described as r2) between SNPs are indicated for
A) LEPR, B) PPARG, C) GHSR and D) LEP, respectively.
160 J. Zhao et al. / Clinical Immunology 161 (2015) 157–162candidate leptin-related genes LEP, LEPR, GHSR and PPARG were per-
formed in different ancestral groups. Information and SNPs scoring are
reported in Supplementary Table 1. Using Illuminamicroarray platform,
15,706 case-control samples from four ethnic groupswere genotyped in
LLAS2 including European American (EA), African American (AA), East
Asian (AS) andHispanic enriched for the Amerindian–European admix-
ture (HS).
In LEP, theA allele of rs12706832 showed associationwith decreased
risk of SLE in AA (78.3% in cases vs. 80.6% in controls, P=0.0063, OR=
0.84, Table 1). In addition, the A allele of rs3828942was associatedwith
increased risk of SLE in AA (19.5% in cases vs. 17.7% in controls, P =
0.029, OR = 1.16, Table 1)
In LEPR, two SNPs rs6690625 and rs1892535 showed association
with decreased risk of SLE in HS (C allele of rs6690625, 25.9% in cases
vs. 28.7% in controls, P = 0.0011, OR = 0.79; A allele of rs1892535,
25.0% in cases vs. 26.8% in controls, P= 0.0068, OR = 0.82, Table 1).
In GHSR, the G allele of rs2948694 was associated with decreased
risk of SLE in HS (13.7% in cases vs. 15.3% in controls, P = 0.019,
OR = 0.81, Table 1).
In PPARG, two SNPs rs12633551 and rs3856806 were associated
with decreased risk of SLE in EA (A allele of rs12633551, 2.8% in cases
vs. 3.3% in controls, P = 0.022, OR = 0.80; A allele of rs3856806,
11.1% in cases vs. 12.3% in controls, P= 0.023, OR = 0.88, Table 1).Although we detected signiﬁcant association signals at several loci,
none of them showed consistent association (P b 0.05) in multiple an-
cestral groups. The meta-analysis combining all four ancestral groups
showed that multiple SNPs in PPARG exhibited association with SLE
(Pmeta = 0.031, 0.024, 0.025, 0.0080 and 0.024 for rs6785890,
rs10510410, rs12633551, rs4145574 and rs3856806, respectively,
Table 1). After Bonferroni correction for multiple tests, only the associa-
tion of rs6690625 in LEPR with SLE in HS remained signiﬁcant (P =
0.0011, which was less than the corrected P= 0.05/32 = 0.0016).
Together, these data do not provide evidence that leptin-related
genes can increase risk for SLE.
4. Discussion
In SLE, many candidate genes including MHC loci, complement
components, mannose-binding protein, Fc-γ receptors and pro-
inﬂammatory cytokines have been tested by genetic association studies
for risk of SLE [21,22]. Recently, the role of leptin receptor polymor-
phism as a possible contributor to SLE risk was suggested [6]. In the
LEPR, several SNPs gene have been identiﬁed, including the Q223R poly-
morphism in which an A to G transition in exon 6 (that encodes for the
extracellular domain of the leptin receptor) [23] could lead to altered
signal transduction by altering binding to leptin and/or by impairing
161J. Zhao et al. / Clinical Immunology 161 (2015) 157–162LEPR expression. Afroze and colleagues found that carriers of variant ge-
notype (A/G+G/G) or G allele were at elevated risk for SLE [6]. Howev-
er, the number of SLE patients in that study was so low that it lacked
power to reach any relevant conclusion as for the association between
leptin receptor and SLE. Conversely, our study uses very large number
of SLE subjects and is well powered, thus the conclusions can be consid-
ered highly signiﬁcant.
Genetics plays a key role in the pathogenesis of autoimmune dis-
eases because it can inﬂuence the expression and activity of genes
that are relevant to the disease. Here we aimed to address whether
the abnormally increased levels of leptin in SLE patients could associate
to gene polymorphisms, i.e. whether certain leptin-related polymor-
phisms might contribute to a predisposing SLE background that would
sustain hyperleptinemia. Although initial assessments suggested the
possibility of associated polymorphisms, extensive analyses on 15,706
individuals of multiple ancestries did not conﬁrm the ﬁndings. Howev-
er, we acknowledge that our results do not exclude the possibility that
other polymorphisms different from the ones tested here and related
to leptin activities could associatewith increased susceptibility to devel-
op SLE.
The ﬁnding of a lack of polymorphisms association with the leptin
pathway reminds the results obtained in genetic association studies
of human BLyS and SLE. Like leptin, BLyS is an important pro-
inﬂammatory cytokine that is abnormally elevated in SLE patients
[24]. However, no polymorphism in BLyS or BlyS receptor BCMA was
found associated with SLE [25,26], possibly because the increase of
BLyS levels in SLE patients could be an indirect consequence of other
gene(s) associated with SLE or a consequence of multiple interactions
between genes and/or genes and environment. It derives that after
our ﬁndings, follow-up multivariate analyses on subsets of patients
(i.e., based on autoantibody positivity, disease manifestations, organ in-
volvement etc.) should be performed for possible identiﬁcation of asso-
ciations and assessment of functional signiﬁcance, to address whether
stratiﬁcation of SLE patients might identify associations of selected
SNPs polymorphisms with deﬁned subsets of patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2015.09.007.
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